| Rank | Stock | Price | Rev. Gr. | Dist. 52WH | Perf. 20D |
|---|---|---|---|---|---|
| WKN | Symbol | EPS Growth | Rel. Strength | |||
| 1 | Krystal Biotech | 318.78 $ | 25.15 % | 0.22 % | 2.77 % |
| A2JH2F | KRYS | 79.81 % | 91 | |||
| 2 | Rush Street Interactive | 28.94 $ | 28.20 % | 1.04 % | 5.18 % |
| A2QK2P | RSI | 328.16 % | 90 | |||
| 3 | StoneX Group | 123.62 $ | 23.82 % | 1.44 % | 5.83 % |
| A2P8CE | SNEX | 44.81 % | 90 | |||
| 4 | Lam Research | 342.95 $ | 26.53 % | 1.76 % | 18.57 % |
| A40L1V | LRCX | 47.33 % | 97 | |||
| 5 | PDF Solutions | 59.69 $ | 24.44 % | 1.94 % | 17.15 % |
| 541307 | PDFS | 500.00 % | 95 | |||
| 6 | Eli Lilly | 1,152.16 $ | 47.44 % | 2.58 % | 16.39 % |
| 858560 | LLY | 128.33 % | 74 | |||
| 7 | Vita Coco Company | 76.99 $ | 23.05 % | 3.41 % | 3.18 % |
| A3C53H | COCO | 35.51 % | 92 | |||
| 8 | Incyte | 108.40 $ | 21.48 % | 3.46 % | 9.33 % |
| 896133 | INCY | 1,872.97 % | 78 | |||
| 9 | Arrow Electronics | 221.47 $ | 20.49 % | 5.07 % | 9.93 % |
| 855225 | ARW | 91.96 % | 84 | |||
| 10 | Amphenol | 157.81 $ | 54.40 % | 5.52 % | 23.42 % |
| 882749 | APH | 68.94 % | 82 |
| Eli Lilly | |
|---|---|
| 5-year chart | |
| Mkt. cap. | 1.03 T USD |
| P/S 25 | 16.77 |
| P/S 26 | 12.92 |
| P/E 25 | 50.41 |
| P/E 26 | 31.78 |
| Div. Yield 25 | 0.52% |
| Div. Yield 26 | 0.60% |
Eli Lilly is driving its growth through global dominance in the incretin drug market with Mounjaro and Zepbound. Phase 3 data for the new oral formulation Foundayo demonstrate a clear superiority over Novo Nordisk's oral semaglutide in blood sugar control and weight loss. With billion-dollar...